has collaborated with Boehringer Ingelheim Pharmaceuticals to launch an at-home testing programme for patients with chronic kidney disease (CKD).

Both entities will work together to assess the operational aspects of the at-home UACR (urine albumin-to-creatinine ratio) test kit, Minuteful Kidney.’s Minuteful Kidney is claimed to be the first and only US Food and Drug Administration-approved smartphone-driven at-home ACR test for previously untested patients.

By enabling patients to conduct a smartphone-powered test at their preferred time and location, this initiative aims to actively involve them in monitoring their kidney health. This step-in screening helps in the early detection of CKD.

Boehringer Ingelheim medicine and regulatory affairs senior vice-president Lennart Jungersten said: “Early screening and diagnosis is critical in delaying CKD progression and may help reduce the potential for serious complications down the road.

“By collaborating with, the ultimate goal is to increase testing for CKD so that those impacted can be evaluated for the appropriate care management.”

Previous collaborations between and prominent health plans and provider systems have demonstrated that implementing Minuteful Kidney for at-home testing increased testing adherence by up to 50% across previously untested populations, regardless of demographic and socioeconomic variations. US general manager Paula LeClair said: “Increasing test-adherence rates across all demographics and socio-economic groups leads to earlier detection of CKD and provides a path to care for those who need it. This is a true win-win – better health outcomes for patients, as well as potentially reduced healthcare costs.”